MCL1 and acute myeloid leukemia: In summary, these data suggest that treating AML cells with the MCL1-inhibitor S63845 and the MEK-inhibitor trametinib leads to reduced levels of phospho-Ser-RPS6 protein, to inhibition of translation, and induction of apoptosis, as summarized in Figure 3.